Shannon Diversity Index

The Shannon diversity index condenses the bacterial variety detected in your stool into one number. It rises when more bacterial types are present in more even proportions. Researchers use it to study changes during illness, treatment, and recovery, but the number alone cannot establish what caused a change or whether your gut is healthy.

This remains an exploratory health measure. There are no universally accepted clinical cutoffs, and studies haven't established that making treatment decisions from this score improves health outcomes. Its research value comes from describing bacterial communities and comparing them under consistent measurement conditions.

What the Score Captures

Two things go into the score. Richness is the number of distinct bacterial types detected. Evenness describes how similar their proportions are. Picture two forests with fifty tree species each: in one, the species occur in similar numbers, and in the other, a single species makes up nearly every tree. The first forest scores higher, even though the species count is identical.

For this stool measurement, the lab sequences bacterial DNA, groups the sequences into bacterial types, and calculates the score from their relative proportions. Those proportions don't measure the total number of bacteria in your gut. A sample dominated by one type has a lower score than a sample with the same types distributed more evenly.

Stool represents bacteria shed into the intestinal contents. Communities attached to the gut lining can differ, so a stool score and a score calculated from a colon biopsy describe different samples. The number also leaves out information about what individual bacteria do.

Age matters. Longitudinal research shows that bacterial diversity develops through infancy and early childhood. Adult comparisons therefore don't provide an appropriate benchmark for a young child.

Serious Illness and Infection Risk

Some of the clearest outcome associations come from hospitals. In a study of 96 people in intensive care, each one-point decline in stool Shannon diversity during the early hospital course was associated with about double the rate of death within 60 days. Diversity typically fell by about a tenth of a point per day, so a one-point loss is a large change. The estimate was imprecise, and the study couldn't establish that the diversity loss caused the deaths.

A study of 97 people starting chemotherapy for acute myeloid leukemia found a similar association with infection. Those with higher baseline stool diversity had roughly two-thirds lower rates of infection before their infection-fighting white blood cells recovered. In a separate leukemia cohort, greater variation in stool diversity during treatment was associated with infections during the following recovery period.

A single reading at intensive care admission has been less consistent. A meta-analysis found that the pooled association between high versus low diversity and in-hospital mortality was too imprecise to support a reliable prediction. These studies used different populations, sampling schedules, and laboratory methods.

The hospital findings don't provide a personal risk estimate for a healthy adult. They also don't establish that collecting a baseline before a planned hospital stay or chemotherapy improves care. Repeated measurements are being studied, but their role in treatment decisions remains unproven.

Ulcerative Colitis and Crohn's Disease

People with inflammatory bowel disease often have lower stool bacterial diversity than healthy comparison groups. Some studies also find lower diversity during active Crohn's disease than during remission, although the distributions overlap.

In a study that included 111 people across ulcerative colitis and healthy comparison groups, the participants with ulcerative colitis in remission were followed for two years. Higher baseline Shannon diversity was associated with about five times the odds of remaining in remission after adjustment for other factors. The estimate was imprecise: the plausible range ran from about 1.5 to about 20. That is an odds comparison from one cohort, not a fivefold increase in your probability of staying flare-free.

This makes diversity a candidate marker for further study, but it doesn't establish a treatment target or a reliable warning of an approaching flare. Symptoms, fecal calprotectin, and other established assessments remain the basis for evaluating inflammatory bowel disease activity.

Blood Sugar, Liver Fat, and Weight

In a study of 2,166 adults, higher stool Shannon diversity was associated with less insulin resistance among people without diabetes. Insulin resistance develops when cells respond less effectively to insulin. The link with type 2 diabetes itself was less secure; the clearest diabetes finding involved the number of bacterial types rather than the Shannon score.

Lower stool diversity was associated with fatty liver in a population study of 1,355 adults, and the link held after accounting for body weight, alcohol, diet, and acid-reducing medication. A meta-analysis also found slightly lower Shannon diversity in women with polycystic ovary syndrome, with a clearer difference in comparisons involving women with obesity. These findings describe group differences; they don't establish that low diversity causes either condition.

Obesity has a less consistent relationship with the score in individual studies. A meta-analysis of seven studies found no statistically clear pooled difference in Shannon diversity between people with and without obesity, with large variation between studies. A later pooled analysis of individual data from 7,415 adults in eight European cohorts, using harmonized methods, found a modest pattern: higher body mass index went with slightly lower diversity. The score still cannot diagnose a metabolic problem or establish that blood sugar or liver health has improved.

Colon and Rectal Cancer

In a study of 166 people with stage I to III colorectal cancer, higher diversity in stool collected before surgery was associated with better disease-free survival, most strongly in the rectal cancer subgroup. This is an exploratory prognostic finding, with no established role in choosing treatment.

Screening research has produced mixed results. In 538 people with usable samples from one health plan's screening program, Shannon diversity wasn't consistently associated with precancerous growths or cancer. A later study of 925 people that sequenced leftover screening-test stool more broadly found lower diversity in people with colorectal growths, especially early adenomas, where higher diversity went with about half the odds. A cross-sectional study of 1,762 people found only weak, inconsistent associations and no reliable bacterial signature. Studies that reuse stool from fecal immunochemical test devices also handle samples differently from a dedicated microbiome kit. Shannon diversity hasn't been validated as a replacement for colorectal cancer screening.

When a Higher Score Isn't Better

The score describes variety without assigning a health value to each organism. A community containing potentially harmful bacteria can be diverse, and two communities with different bacteria can produce the same score.

Research doesn't support a universal pattern across diseases. A pooled reanalysis found no consistent Shannon diversity difference in Parkinson's disease or multiple sclerosis. Psychiatric conditions show no consistent direction either. A meta-analysis of 34 studies found no significant Shannon difference across psychiatric disorders, and a large population cohort linked lower diversity with more depressive symptoms. One small study even reported higher fecal diversity in people with active major depression than in healthy controls.

Higher bacterial diversity has also been reported in people carrying Blastocystis. This organism isn't a bacterium, so its presence doesn't directly add to a bacterial Shannon score. The association describes the bacterial community accompanying carriage; it doesn't establish whether carriage is beneficial or harmful.

When Results Can Be Misleading

• Laboratory methods: DNA extraction, the sequencing approach, the amount of sequencing, and the way sequences are grouped can change the result. Scores from different laboratories or analytical pipelines aren't automatically comparable.
• Calculation choices: the logarithm used in the formula changes the numerical scale. A transformed measure such as the effective number of bacterial types is also different from the raw Shannon index.
• Collection and storage: preservation, temperature, and delays before processing can alter the bacterial proportions measured in a sample.
• Stool consistency: stool consistency and intestinal transit can accompany differences in bacterial communities. A small study found limited changes during ordinary day-to-day variation, but that doesn't establish that diarrhea or constipation has no effect.
• Recent treatment or illness: antibiotics, cancer treatment, and serious illness can cause real biological changes. A sample collected during these events describes that period and may differ from your usual state.
• Single-sample noise: a meaningful share of Shannon variation occurs within the same person over time, so one sample can sit above or below your usual level.
• Relative proportions: the score can change when one group expands, even without a loss of every other group. It doesn't measure total bacterial quantity, confirm that detected bacteria are alive, or identify the cause of symptoms.

Tracking Your Trend

In a small study of 25 older adults, stool Shannon diversity was fairly stable over two years. A study with dense repeated sampling paints a noisier picture: about a third of the variation in Shannon diversity occurred within the same person over time, and evenness varied even more. One reading can misrepresent your usual state, and no study has established how large a change must be to matter clinically. A return to an earlier score also doesn't prove that the original bacterial community or its functions have returned.